Swiss Startup Comphya Secures €8M To Tackle Erectile Dysfunction

The company is developing the first implantable neurostimulation therapy for erectile dysfunction (ED) that does not respond to medication. Including converted convertible loans, Comphya has now raised a total of €8 million in equity funding.

“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer,” said Pim van Wesel, CEO of Comphya. “With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we’re entering an important new chapter in our development.”

Founded in 2017 as a spin-off from EPFL, Comphya is a MedTech company developing CaverSTIM, the first implantable neurostimulation system aimed at restoring erectile function in men who don’t respond to oral medication.

CaverSTIM consists of an implantable pulse generator (IPG) with a rechargeable battery and an electrode array designed to stimulate cavernous nerves in the pelvic region. The IPG is implanted under the skin in the lower abdomen and is operated externally by both clinicians and patients—allowing personalized and on-demand therapy.

Read Also - German Circonomit Secures €2.8Million In Seed Round

Currently, men with severe ED must rely on painful intrapenile injections or outdated implants. Comphya aims to change that by offering a solution that mimics natural function and improves quality of life.

Proceeds from the €8M Series A round will support a pilot study in the U.S. at Johns Hopkins (following FDA IDE approval), expansion of the ongoing Australian clinical trial, and preparations for a pivotal U.S. trial in 2026.

Early results from Australian trials have shown strong safety and efficacy, with most patients retaining erectile function without additional therapies and no adverse events reported. The U.S. study will build on this momentum.

The company also appointed Pim van Wesel as CEO in May 2025 to lead its next phase of clinical and strategic development. Comphya’s CaverSTIM is positioned as the first implantable solution to restore natural erectile function through direct nerve stimulation.

About Comphya

Comphya is a Swiss MedTech spin-off from EPFL, developing innovative neuroprosthetic solutions for erectile dysfunction (ED), especially in patients unresponsive to medication due to spinal cord injuries or prostate surgery. Its implantable device aims to safely restore natural function and improve quality of life for men worldwide.